NHS fast-tracks new therapy for rare ‘graft vs host’ disease

Cancer patients living with a rare disease which attacks the body’s own organs following a life-saving stem cell transplant are set to benefit from a pioneering new medicine on the NHS. Belumosudil (Rezurock ®) is an innovative treatment for chronic graft versus host disease, which develops in around a third of patients who have undergone […]

Read More  on the NHS website.